Skip to content

Harrow HROW EV / sales

EV / sales at other companies

AbbVie logo
AbbVieABBV
7.5×+1.0×
Bausch + Lomb logo
Bausch + LombBLCO
0.0×
Ocular Therapeutix logo
Ocular TherapeutixOCUL
24.1×+9.2×
Viatris logo
ViatrisVTRS
1.9×+0.3×
Bausch Health Companies logo
Bausch Health CompaniesBHC
-0.3×
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
5.6×-3.1×

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.59B+38.4%

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Calculated from Harrow’s reported figures.

Based on the most recent quarter.

The official record: Harrow’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harrow's EV / sales?
Harrow (HROW) reported EV / sales of 5.7× in Q1 2026.
How has Harrow's EV / sales changed year-over-year?
Harrow's EV / sales decreased by 9.8% year-over-year, from 6.3× to 5.7×.
What is the long-term trend for Harrow's EV / sales?
Over 4 years (2021 to 2025), Harrow's EV / sales has grown at a 15.3% compound annual growth rate (CAGR), from 4.2× to 7.3×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.